These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 7596218

  • 1. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
    Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N.
    Life Sci; 1995; 57(1):23-9. PubMed ID: 7596218
    [Abstract] [Full Text] [Related]

  • 2. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N.
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J, Gao HX, Yang N, Zhu XD, Sun RB, Xie Y, Zeng CH, Zhang JW, Wang JK, Ding F, Aa JY, Wang GJ.
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [Abstract] [Full Text] [Related]

  • 6. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H, Takamura T, Nagai Y, Kaneko S, Kanazawa University Multicenter Diabetes Study Group.
    J Diabetes Complications; 2006 Jan; 20(6):367-70. PubMed ID: 17070440
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
    Asano T, Saito Y, Kawakami M, Yamada N, Fidarestat Clinical Pharmacology Study Group.
    J Diabetes Complications; 2002 Jan; 16(2):133-8. PubMed ID: 12039395
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H, Aoki T, Sassa H, Suzuki T, Taniko K, Makino M, Mizuno K, Suzuki T.
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
    Tsugawa T, Shinohara R, Nagasaka A, Nakano I, Takeda F, Nagata M, Oda N, Sawai Y, Hayakawa N, Suzuki A, Itoh M.
    J Endocrinol; 2004 Jun; 181(3):429-35. PubMed ID: 15171691
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Identification of sorbitol 3-phosphate and fructose 3-phosphate in normal and diabetic human erythrocytes.
    Petersen A, Szwergold BS, Kappler F, Weingarten M, Brown TR.
    J Biol Chem; 1990 Oct 15; 265(29):17424-7. PubMed ID: 2211634
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T, Shimada A, Itoh H.
    J Diabetes Complications; 2010 Oct 15; 24(6):424-32. PubMed ID: 19716319
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
    Hamada Y, Nishimura C, Koh N, Sakakibara F, Nakamura J, Tanimoto T, Hotta N.
    Diabetes Care; 1998 Jun 15; 21(6):1014-8. PubMed ID: 9614624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.